For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Research and development | 8,542 | 7,296* | ||
| General and administrative | 6,867 | 3,067* | ||
| Total operating expenses | 15,409 | 10,362 | ||
| Loss from operations | -15,409 | -10,362* | ||
| Interest income | 1,591 | 777* | ||
| Change in fair value of redeemable convertible preferred stock tranche liability | 0 | 382* | ||
| Total other income (expense) | 1,591 | 395* | ||
| Loss before income tax | -13,818 | -9,967* | ||
| Federal | - | 0* | ||
| State | - | 0* | ||
| Foreign | - | 0* | ||
| Total current taxes | - | 0* | ||
| Federal | - | 2,177* | ||
| State | - | 302* | ||
| Foreign | - | 0* | ||
| Total deferred taxes | - | 2,478* | ||
| Valuation allowance | - | -2,477* | ||
| Income tax provision | 0 | 0* | ||
| Net loss | -13,818 | -9,967 | ||
| Basic EPS | -0.69 | -4.496 | ||
| Diluted EPS | -0.69 | -4.496 | ||
| Basic Average Shares | 19,927,848 | 2,217,104 | ||
| Diluted Average Shares | 19,927,848 | 2,217,104 | ||
SpyGlass Pharma, Inc. (SGP)
SpyGlass Pharma, Inc. (SGP)